Poster presentation at the AACR annual meeting 2021
Minerva Imaging are happy to share the use of our preclinical models in the development of OP-1250, a complete estrogen receptor antagonist, or CERAN, and a selective estrogen receptor (ER) degrader.
Efficacy of OP-1250 was evaluated in an intracranial patient derived xenograft (PDX) tumor model with breast cancer cells expressing mutant estrogen receptor (ESR1-Y537S). OP-1250 treatment was superior in shrinking ST941 ER+ tumors compared to other endocrine therapies tested, including ovariectomy, fulvestrant and tamoxifen.
The studies were conducted in collaboration with Olema Oncology and presented at the American Association for Cancer Research annual meeting 2021 in the session of Novel Antitumor Agents (poster #LB122).
Thanks to Olema Oncology for choosing us as their collaborator to perform the studies evaluating their product candidate OP-1250. OP-1250 is currently in a phase I/II dose escalation and expansion clinical trial in breast cancer patients with recurrent, locally advanced or metastatic ER+/HER2- tumors whose disease has progressed on prior endocrine therapy.
Minerva Imaging has a long-term collaboration with XenoSTART on the use of their extensive catalogue of validated and characterized PDX models for studies in the orthotopic and metastatic setting and studies involving external radiation therapy, radionuclide therapy and in vivo imaging.